CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033

February 2026 | 150 pages | ID: C6557773AFE1EN
Grand View Research, Inc.

Abstracts

The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.

Rising Cancer Burden

The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient’s T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.

Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.

Global CAR T-cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Others
• Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Leukemia
• Lymphoma
• Multiple Myeloma
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Cancer Treatment Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• Rest of World

This report can be delivered to the clients within 3 Business Days

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation and Scope
  1.1.1. Segment Definitions
    1.1.1.1. Product Segment
    1.1.1.2. Disease Indication Segment
    1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
  1.4.1. Objective
  1.4.2. Objective2
1.5. Research Methodology
1.6. Information Procurement
  1.6.1. Purchased Database
  1.6.2. GVR’s Internal Database
  1.6.3. Secondary Sources
  1.6.4. Primary Research
1.7. Information or Data Analysis:
  1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
  1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE

3.1. Market Lineage Outlook
  3.1.1. Parent Market Outlook
  3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
  3.2.1. Market Driver Analysis
    3.2.1.1. Rising cancer burden
    3.2.1.2. Personalized treatment advantage
  3.2.2. Market Restraint Analysis
    3.2.2.1. Regulatory complexity
3.3. Industry Analysis Tools
  3.3.1. Porter’s Five Forces Analysis
  3.3.2. PESTEL Analysis

CHAPTER 4. PRODUCT BUSINESS ANALYSIS

4.1. Product Segment Dashboard
4.2. CAR T-cell Therapy Market: Product Movement Analysis
4.3. Abecma (idecabtagene vicleucel)
  4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
4.4. Breyanzi (lisocabtagene maraleucel)
  4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
4.5. Carvykti (ciltacabtagene autoleucel)
  4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
4.6. Kymriah (tisagenlecleucel)
  4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
4.7. Tecartus (brexucabtagene autoleucel)
  4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
4.8. Yescarta (axicabtagene ciloleucel)
  4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
4.9. Others
  4.9.1. Others market, 2021 - 2033 (USD Million)

CHAPTER 5. DISEASE INDICATION BUSINESS ANALYSIS

5.1. Disease Indication Segment Dashboard
5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
5.3. Leukemia
  5.3.1. Leukemia market, 2021 - 2033 (USD Million)
5.4. Lymphoma
  5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
5.5. Multiple Myeloma
  5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
5.6. Others
  5.6.1. Others market, 2021 - 2033 (USD Million)

CHAPTER 6. END USE BUSINESS ANALYSIS

6.1. End Use Segment Dashboard
6.2. CAR T-cell Therapy Market: End Use Movement Analysis
6.3. Hospitals
  6.3.1. Hospitals market, 2021 - 2033 (USD Million)
6.4. Cancer treatment centers
  6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)

CHAPTER 7. REGIONAL BUSINESS ANALYSIS

7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
7.2. North America
  7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.2.2. U.S.
    7.2.2.1. Key Country Dynamics
    7.2.2.2. Competitive Scenario
    7.2.2.3. Regulatory Framework
    7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.2.3. Canada
    7.2.3.1. Key Country Dynamics
    7.2.3.2. Competitive Scenario
    7.2.3.3. Regulatory Framework
    7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
7.3. Europe
  7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.3.2. UK
    7.3.2.1. Key Country Dynamics
    7.3.2.2. Competitive Scenario
    7.3.2.3. Regulatory Framework
    7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.3.3. Germany
    7.3.3.1. Key Country Dynamics
    7.3.3.2. Competitive Scenario
    7.3.3.3. Regulatory Framework
    7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
7.4. Asia Pacific
  7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.4.2. Japan
    7.4.2.1. Key Country Dynamics
    7.4.2.2. Competitive Scenario
    7.4.2.3. Regulatory Framework
    7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  7.4.3. China
    7.4.3.1. Key Country Dynamics
    7.4.3.2. Competitive Scenario
    7.4.3.3. Regulatory Framework
    7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
7.5. Rest of World
  7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Position Analysis, 2025
8.4. Company Profiles/Listing
  8.4.1. Bristol-Myers Squibb Company
    8.4.1.1. Overview
    8.4.1.2. Financial Performance
    8.4.1.3. Product Benchmarking
    8.4.1.4. Strategic Initiatives
  8.4.2. Novartis AG
    8.4.2.1. Overview
    8.4.2.2. Financial Performance
    8.4.2.3. Product Benchmarking
    8.4.2.4. Strategic Initiatives
  8.4.3. Gilead Sciences, Inc.
    8.4.3.1. Overview
    8.4.3.2. Financial Performance
    8.4.3.3. Product Benchmarking
    8.4.3.4. Strategic Initiatives
  8.4.4. Johnson & Johnson Services, Inc.
    8.4.4.1. Overview
    8.4.4.2. Financial Performance
    8.4.4.3. Product Benchmarking
    8.4.4.4. Strategic Initiatives
  8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
    8.4.5.1. Overview
    8.4.5.2. Financial Performance
    8.4.5.3. Product Benchmarking
    8.4.5.4. Strategic Initiatives
  8.4.6. bluebird bio, Inc.
    8.4.6.1. Overview
    8.4.6.2. Financial Performance
    8.4.6.3. Product Benchmarking
    8.4.6.4. Strategic Initiatives
  8.4.7. Merck & Co., Inc.
    8.4.7.1. Overview
    8.4.7.2. Financial Performance
    8.4.7.3. Product Benchmarking
    8.4.7.4. Strategic Initiatives
  8.4.8. Sangamo Therapeutics
    8.4.8.1. Overview
    8.4.8.2. Financial Performance
    8.4.8.3. Product Benchmarking
    8.4.8.4. Strategic Initiatives
  8.4.9. Sorrento Therapeutics, Inc.
    8.4.9.1. Overview
    8.4.9.2. Financial Performance
    8.4.9.3. Product Benchmarking
    8.4.9.4. Strategic Initiatives
  8.4.10. GSK plc.
    8.4.10.1. Overview
    8.4.10.2. Financial Performance
    8.4.10.3. Product Benchmarking
    8.4.10.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1. Global CAR T-cell therapy market, by region, 2021 - 2033 (USD Million)
Table 2. Global CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 3. Global CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 4. Global CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 5. North America CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
Table 6. North America CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 7. North America CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 8. North America CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 9. U.S. CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 10. U.S. CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 11. U.S. CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 12. Canada CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 13. Canada CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 14. Canada CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 15. Europe CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
Table 16. Europe CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 17. Europe CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 18. Europe CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 19. UK CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 20. UK CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 21. UK CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 22. Germany CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 23. Germany CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 24. Germany CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 25. Asia Pacific CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
Table 26. Asia Pacific CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 27. Asia Pacific CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 28. Asia Pacific CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 29. Japan CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 30. Japan CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 31. Japan CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 32. China CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 33. China CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 34. China CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
Table 35. Rest or World CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
Table 36. Rest of World CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
Table 37. Rest of World CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
Table 38. Rest of World CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

Fig. 1 CAR T-cell therapy market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Market trends & outlook
Fig. 16 PESTEL analysis
Fig. 17 Porter’s five forces analysis
Fig. 18 CAR T-cell therapy market: Product outlook & key takeaways
Fig. 19 CAR T-cell therapy market: Product movement analysis
Fig. 20 Global abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
Fig. 21 Global breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
Fig. 22 Global carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
Fig. 23 Global kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
Fig. 24 Global tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
Fig. 25 Global yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
Fig. 26 Global others market, 2021 - 2033 (USD Million)
Fig. 27 CAR T-cell therapy market: Disease Indication outlook key takeaways
Fig. 28 CAR T-cell therapy market: Disease Indication movement analysis
Fig. 29 Global leukemia market, 2021 - 2033 (USD Million)
Fig. 30 Global lymphoma market, 2021 - 2033 (USD Million)
Fig. 31 Global multiple myeloma market, 2021 - 2033 (USD Million)
Fig. 32 Global others market, 2021 - 2033 (USD Million)
Fig. 33 CAR T-cell therapy market: End Use outlook key takeaways
Fig. 34 CAR T-cell therapy market: End Use movement analysis
Fig. 35 Global hospitals market, 2021 - 2033 (USD Million)
Fig. 36 Global cancer treatment centers market, 2021 - 2033 (USD Million)
Fig. 37 Regional outlook
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 North America CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 US CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Canada CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Europe CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Germany CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Key country dynamics
Fig. 48 UK CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Asia Pacific CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Japan CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 China CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 Rest of World CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)